癌/睾丸抗原在肺癌中的研究进展
|
摘要
肺癌传统的诊治手段难以达到满意的效果。寻找新的早期诊断和治疗方法迫在眉睫。很多研究表明癌/睾丸抗原(CTA)与肺癌的分期、病理类型、转移、复发等密切相关,在肺癌的免疫治疗中,CTA备受瞩目,其表达特性对肺癌诊疗方法的发展有着重要意义。现就CTA与肺癌关系的研究进展做如下综述。
Traditional diagnosis and treatment methods of lung cancer are difficult to take satisfactory effect. Therefore,it is urgent to search for new modalities for early diagnosis and novel treatment. Many studies have shown that cancer/testis antigens( CTA) correlate with cancer staging,pathology subtypes,metastasis and recurrence closely,especially in the immunotherapy of lung cancer. CTA is very high-profile and of great significance for the development of diagnosis and treatment of lung cancer because of its expression characteristics. The research progress of the relationship between CTA and lung cancer is summarized as follows.
Traditional diagnosis and treatment methods of lung cancer are difficult to take satisfactory effect. Therefore,it is urgent to search for new modalities for early diagnosis and novel treatment. Many studies have shown that cancer/testis antigens( CTA) correlate with cancer staging,pathology subtypes,metastasis and recurrence closely,especially in the immunotherapy of lung cancer. CTA is very high-profile and of great significance for the development of diagnosis and treatment of lung cancer because of its expression characteristics. The research progress of the relationship between CTA and lung cancer is summarized as follows.
引文
[1] Siegel RL,Miller KD,Ahmedin Jemal DVM. Cancer statistics,2017[J]. Ca A Cancer J Clinicians,2017,67(1):7-30.
[2] Vander Bruggen,Traversari C,Chomez P,et al. A gene encoding an antigen recognized by cyolytic T lymphocytes on a human melanom[J]. Science,1991,254(5038):1634-1647.
[3] Grizzi F,Mirandola L,Qehajaj D,et al. Cancer-testis antigens and immunotherapy in the light of cancer complexity[J]. Int Rev Immunol,2015,34(2):143-153.
[4] Talebian YM,Loof NM. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunother,2015,64(9):1109-1121.
[5] Gu L,Sang M,Yin D,et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer[J]. Thoracic Cancer,2018(1):431-438.
[6] Chen X,Wang L,Liu J,et al. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer[J]. Oncology Letters,2017,13(3):1609-1618.
[7] Taguchi A,Taylor AD,Rodriguez J,et al. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes,expanding the repertoire of potential immunotherapeutic targets[J].Cancer Res,2014,74(17):4694-4705.
[8] Grah JJ,Katalinic D,Juretic A,et al. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens(MAGE-A1,MAGE-A3/4,NY-ESO-1)in patients with non-small cell lung cancer[J]. Tumori,2014,100(1):60-80.
[9] Greve KB,Phl M,Olsen KE,et al. SSX2-4 expression in earlystage non-small cell lung cancer[J]. Tissue Antigens,2014,83(5):344-349.
[10] Sang M,Gu L,Yin D,et al. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma:A retrospective clinical study based on tissue microarray[J]. J Clinical Pathol,2017,70(6):533-540.
[11] Chen X,Wang M,Yue D,et al. Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance[J]. J Immunother Cancer,2013,1(1):1.
[12] Thongprasert S,Yang PC,Lee JS,et al. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients[J]. Lung Cancer,2016,101:137-144.
[13] Han XJ,Lin YE,Xiang B,et al. Clinacal significance of MAGEA3 and AKAP-4 in non-small lung carcinoma[J]. J Tropical Med,2012,12(9):1068-1070.[韩秀晶,林云恩,向波,等.探索MAGE-A3和AKAP-4在非小细胞肺癌中的表达及意义[J].热带医学杂志,2012,12(9):1068-1070.]
[14] Li H,Guo K,Yu X,et al. Expression and clinical significance of A-kinase anchor protein 4 in lung adenocarcinoma tissue[J]. Thoracic Cancer,2016,7(3):273-278.
[15] Talebian YM,Loof NM,Franken KL,et al. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunotherapy,2015,64(9):1109-1121.
[16] Sardaro A,Saito K,Nakayama E,et al. Correction:Immune responses to the cancer testis antigen XAGE-1b in non small cell lung cancer caucasian patients[J]. PLo S One,2016,11(3):e0150623.
[17] Su C,Xu Y,Li X,et al. Predictive and prognostic effect of CD133and cancer-testis antigens in stage Ib-Ⅲanon-small cell lung cancer[J]. International J Clin Exp Pathol,2015,8(5):5509.
[18] Oshima Y,Shimada H,Yajima S,et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer:Screening in 1969 patients with various cancers[J]. J Gastroenterol,2016,51(1):30-34.
[19] Gjerstorff MF,Phl M,Olsen KE,et al. Analysis of GAGE,NYESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma[J]. Bmc Cancer,2013,13(1):1-6.
[20] Hanagiri T,Shigematsu Y,Shinohara S,et al. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer[J]. Anticancer Res,2013,33(5):2123-2128.
[21] Manoj Grag,Dipak Chaurasiya,Ritu Ranan,et al. Sperm-associated antigen 9. A novel cancer testis antigen,is a potential target for immunotherapy in epithelial ovarian cancer[J]. Cancer Res,2007,13(5):1421-1428.
[22] Ren B,Wei X,Zou G,et al. Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer[J]. Oncology Reports,2016,35(5):2599-2605.
[23] Koinuma J,Akiyama H,Fujita M,et al. Characterization of an Opa interacting protein 5 involved in lung andesophageal carcinogenesis[J]. Cancer Sci,2012,103(3):577-586.
[24] Mirandola L,Figueroa JA,Phan TT,et al. Novel antigens in nonsmall cell lung cancer:SP17,AKAP4,and PTTG1 are potential immunotherapeutic targets[J]. Oncotarget,2015,6(5):2812-2826.
[25] Chirivainternati M,Pandey A,Saba R,et al. Cancer testis antigens:A novel target in lung cancer[J]. Int Rev Immunol,2012,31(5):321-343.
[26] Luo C,Xiao X,Liu D,et al. CABYR is a novel cancer-testis antigen in lung cancer[J]. Clin Cancer Res,2007,13(4):1288-1297.
[27] Qian Z,Li M,Wang R,et al. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through in activation of Akt[J]. Mol Cancer Res,2014,12(3):335-347.
[28] Ollinger R,Alsheimer M,Benavente R. Mammalian protein SCP1forms synaptonnemal complex-like structures in the absence of meiotic chromosomes[J]. Mol Biol Cell,2015,16(1):212-217.
[29] Kirkin AF,Dzhandzhugazyan KN,Guldberg P,et al. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells[J]. Nature Commun,2018,9(1):785-790.
[30] Wang Q,Li X,Ren S,et al. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer[J]. PLo S One,2015,10(4):e0122792.
[31] MyíkováD,Adkins I,Nad'a H,et al. Case-control study:Smoking history affects the production of tumor antigen specific antibodies NY-ESO-1 in patients with lung cancer in comparison with cancer disease free group[J]. Journal of Thoracic Oncol,2016,12(2):249-260.
[32] Yi E,Chang JE,Leem C,et al. Association of MAGE A1-6 expression with lung cancer progression[J]. J Cancer,2017,8(8):1324-1329.
[33] Zhai X,Xu L,Zhang S,et al. High expression levels of MAGEA9 are correlated with unfavorable survival in lung adenocarcinoma[J]. Oncotarget,2016,7(4):4871-4881.
[34] Yang J,Jiao S,Kang J,et al. Application of serum NY-ESO-1antibody assay for early SCLC diagnosis[J]. Int J Clin Exp Pathol,2015,8(11):14959-14964.
[35] Shigematsu Y,Hanagiri T,Shiota H,et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer[J]. Lung Cancer,2010,68(1):105-110.
[36] Vansteenkiste JF,Cho BC,Vanakesa T,et al. Efficacy of the MAGEA3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncology,2016,17(6):822-835.
[37] Wada H,Isobe M,Kakimi K,et al. Vaccination with NY-ESO-1 overlapping peptides mixed with picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen[J]. J Immunother,2014,37(2):84-92.
[38] Yue FH,Chu M,Shi C,et al. Cancer testis antigen expression and regulation of A549 and biological meaning[J]. Progress in Modern Biomedicine,2014,14(1):1-6.[岳芳桦,初明,史萃,等.A549肺癌细胞株中癌睾丸抗原的表达及生物学意义研究[J].现代生物医学进展,2014,14(1):1-6.]
[2] Vander Bruggen,Traversari C,Chomez P,et al. A gene encoding an antigen recognized by cyolytic T lymphocytes on a human melanom[J]. Science,1991,254(5038):1634-1647.
[3] Grizzi F,Mirandola L,Qehajaj D,et al. Cancer-testis antigens and immunotherapy in the light of cancer complexity[J]. Int Rev Immunol,2015,34(2):143-153.
[4] Talebian YM,Loof NM. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunother,2015,64(9):1109-1121.
[5] Gu L,Sang M,Yin D,et al. MAGE-A gene expression in peripheral blood serves as a poor prognostic marker for patients with lung cancer[J]. Thoracic Cancer,2018(1):431-438.
[6] Chen X,Wang L,Liu J,et al. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer[J]. Oncology Letters,2017,13(3):1609-1618.
[7] Taguchi A,Taylor AD,Rodriguez J,et al. A search for novel cancer/testis antigens in lung cancer identifies VCX/Y genes,expanding the repertoire of potential immunotherapeutic targets[J].Cancer Res,2014,74(17):4694-4705.
[8] Grah JJ,Katalinic D,Juretic A,et al. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens(MAGE-A1,MAGE-A3/4,NY-ESO-1)in patients with non-small cell lung cancer[J]. Tumori,2014,100(1):60-80.
[9] Greve KB,Phl M,Olsen KE,et al. SSX2-4 expression in earlystage non-small cell lung cancer[J]. Tissue Antigens,2014,83(5):344-349.
[10] Sang M,Gu L,Yin D,et al. MAGE-A family expression is correlated with poor survival of patients with lung adenocarcinoma:A retrospective clinical study based on tissue microarray[J]. J Clinical Pathol,2017,70(6):533-540.
[11] Chen X,Wang M,Yue D,et al. Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance[J]. J Immunother Cancer,2013,1(1):1.
[12] Thongprasert S,Yang PC,Lee JS,et al. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients[J]. Lung Cancer,2016,101:137-144.
[13] Han XJ,Lin YE,Xiang B,et al. Clinacal significance of MAGEA3 and AKAP-4 in non-small lung carcinoma[J]. J Tropical Med,2012,12(9):1068-1070.[韩秀晶,林云恩,向波,等.探索MAGE-A3和AKAP-4在非小细胞肺癌中的表达及意义[J].热带医学杂志,2012,12(9):1068-1070.]
[14] Li H,Guo K,Yu X,et al. Expression and clinical significance of A-kinase anchor protein 4 in lung adenocarcinoma tissue[J]. Thoracic Cancer,2016,7(3):273-278.
[15] Talebian YM,Loof NM,Franken KL,et al. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma[J]. Cancer Immunol Immunotherapy,2015,64(9):1109-1121.
[16] Sardaro A,Saito K,Nakayama E,et al. Correction:Immune responses to the cancer testis antigen XAGE-1b in non small cell lung cancer caucasian patients[J]. PLo S One,2016,11(3):e0150623.
[17] Su C,Xu Y,Li X,et al. Predictive and prognostic effect of CD133and cancer-testis antigens in stage Ib-Ⅲanon-small cell lung cancer[J]. International J Clin Exp Pathol,2015,8(5):5509.
[18] Oshima Y,Shimada H,Yajima S,et al. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer:Screening in 1969 patients with various cancers[J]. J Gastroenterol,2016,51(1):30-34.
[19] Gjerstorff MF,Phl M,Olsen KE,et al. Analysis of GAGE,NYESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma[J]. Bmc Cancer,2013,13(1):1-6.
[20] Hanagiri T,Shigematsu Y,Shinohara S,et al. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer[J]. Anticancer Res,2013,33(5):2123-2128.
[21] Manoj Grag,Dipak Chaurasiya,Ritu Ranan,et al. Sperm-associated antigen 9. A novel cancer testis antigen,is a potential target for immunotherapy in epithelial ovarian cancer[J]. Cancer Res,2007,13(5):1421-1428.
[22] Ren B,Wei X,Zou G,et al. Cancer testis antigen SPAG9 is a promising marker for the diagnosis and treatment of lung cancer[J]. Oncology Reports,2016,35(5):2599-2605.
[23] Koinuma J,Akiyama H,Fujita M,et al. Characterization of an Opa interacting protein 5 involved in lung andesophageal carcinogenesis[J]. Cancer Sci,2012,103(3):577-586.
[24] Mirandola L,Figueroa JA,Phan TT,et al. Novel antigens in nonsmall cell lung cancer:SP17,AKAP4,and PTTG1 are potential immunotherapeutic targets[J]. Oncotarget,2015,6(5):2812-2826.
[25] Chirivainternati M,Pandey A,Saba R,et al. Cancer testis antigens:A novel target in lung cancer[J]. Int Rev Immunol,2012,31(5):321-343.
[26] Luo C,Xiao X,Liu D,et al. CABYR is a novel cancer-testis antigen in lung cancer[J]. Clin Cancer Res,2007,13(4):1288-1297.
[27] Qian Z,Li M,Wang R,et al. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through in activation of Akt[J]. Mol Cancer Res,2014,12(3):335-347.
[28] Ollinger R,Alsheimer M,Benavente R. Mammalian protein SCP1forms synaptonnemal complex-like structures in the absence of meiotic chromosomes[J]. Mol Biol Cell,2015,16(1):212-217.
[29] Kirkin AF,Dzhandzhugazyan KN,Guldberg P,et al. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells[J]. Nature Commun,2018,9(1):785-790.
[30] Wang Q,Li X,Ren S,et al. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer[J]. PLo S One,2015,10(4):e0122792.
[31] MyíkováD,Adkins I,Nad'a H,et al. Case-control study:Smoking history affects the production of tumor antigen specific antibodies NY-ESO-1 in patients with lung cancer in comparison with cancer disease free group[J]. Journal of Thoracic Oncol,2016,12(2):249-260.
[32] Yi E,Chang JE,Leem C,et al. Association of MAGE A1-6 expression with lung cancer progression[J]. J Cancer,2017,8(8):1324-1329.
[33] Zhai X,Xu L,Zhang S,et al. High expression levels of MAGEA9 are correlated with unfavorable survival in lung adenocarcinoma[J]. Oncotarget,2016,7(4):4871-4881.
[34] Yang J,Jiao S,Kang J,et al. Application of serum NY-ESO-1antibody assay for early SCLC diagnosis[J]. Int J Clin Exp Pathol,2015,8(11):14959-14964.
[35] Shigematsu Y,Hanagiri T,Shiota H,et al. Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer[J]. Lung Cancer,2010,68(1):105-110.
[36] Vansteenkiste JF,Cho BC,Vanakesa T,et al. Efficacy of the MAGEA3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncology,2016,17(6):822-835.
[37] Wada H,Isobe M,Kakimi K,et al. Vaccination with NY-ESO-1 overlapping peptides mixed with picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen[J]. J Immunother,2014,37(2):84-92.
[38] Yue FH,Chu M,Shi C,et al. Cancer testis antigen expression and regulation of A549 and biological meaning[J]. Progress in Modern Biomedicine,2014,14(1):1-6.[岳芳桦,初明,史萃,等.A549肺癌细胞株中癌睾丸抗原的表达及生物学意义研究[J].现代生物医学进展,2014,14(1):1-6.]